Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines

A parainfluenza, virus technology, applied in the direction of viruses, viral peptides, antiviral agents, etc.

Inactive Publication Date: 2009-03-25
UNITED STATES OF AMERICA
View PDF10 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] Although BPIV3 is known to have host-range genes that restrict replication in the respiratory tract of macaques, orangutans, and humans, it remains unknown which bovine protein or non-coding sequence determines this host-range restriction of replication

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
  • Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
  • Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0200] Construction of antigenomic cDNA encoding chimeric HPIV3 / BPIV3 and identification of infectious virus recover

[0201] The following three example studies identify proteins that contribute to host range restriction of BPIV3 in primates. The method is to replace the N protein of wild-type HPIV3 virus with the corresponding part on BPIV3. This replacement was accomplished by recovering infectious PIV from cDNA using the reverse genetics system described above. This study started with BPIV3 N because, compared to other HPIV3 and BPIV3 proteins, this protein has modest differences in the amino acid sequence of its HPIV3 counterpart (see Example I).

[0202] A chimeric recombinant virus was constructed, wherein the N ORF of HPIV3 JS strain was replaced by BPIV3 Ka or SF strain ( figure 1 ). These chimeric viruses possess the HN and F glycoproteins of the HPIV3 parent and induce high levels of immunity to HPIV3 in primates. Two chimeric viruses were successfully obta...

Embodiment II

[0211] Replication of HPIV3 / BPIV3 chimeric virus in cell culture

[0212] Efficient replication of live attenuated virus vaccines in tissue culture cells is a feature of the human-bovine chimeric PIV of the present invention, thus enabling efficient production of recombinant vaccine materials. Multicycle replication of rJS parent, cKa, Ka parent, cSF and SF parent in bovine cell line (MDBK) and simian cell line (LLC-MK2) by the method described above (Tao et al., 1998, incorporated herein by reference) To determine, that is, the virus infects the cells with a multiplicity of infection of 0.01, samples were collected (in triplicate) over a period of 5 days ( Figure 5 ). These chimeric viruses replicated as efficiently in both cell lines as their human or bovine parental viruses, without significant delays in replication, or significant reductions in the resulting virus titers. In either case, the chimeric virus replicated to 10 7.0 TCID 50 / ml (i.e., far greater than the...

Embodiment III

[0214] Evaluation of Attenuation and Protection Efficiency of HPIV3 / BPIV3 Chimeric Viruses in Rhesus Monkeys

[0215] Both BPIV3 Ka and SF are attenuated in both the upper and lower airways of rhesus monkeys (van Wyke Coelingh et al., 1988, supra). This attenuated phenotype correlates with attenuation in humans (Karron et al., 1995a, supra), as Ka replication is highly restricted in the upper respiratory tract of sufficiently sensitive seronegative infants and children. Cough, croup, bronchiolitis, or lung disease did not develop in BPIV3-infected vaccinators, suggesting that Ka BPIV3 virus is also attenuated in the lower respiratory tract. Therefore, macaques are considered a widely accepted, reasonably relevant model to assess the attenuation of candidate PIV vaccine viruses and their effectiveness against wild-type PIV.

[0216] rJS, cKa, Ka parent, cSF and SF parent were administered intranasally and intratracheally to rhesus monkeys, 10 per dose per site 5.0 TCID 50 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides attenuated human-bovine parainfluenza viruses (PIVs), mainly comprising a nucleoprotein (N), phosphoprotein (P), and a large polymerase protein (L) and one or more heterogeny genome or antigenome section(s) combining different PIVs, to form partial or integrated PIV background genome or antigenome of human PIV or bovine PIV of human-bovine PIV genome or antigenome, and at least one heterogeny genome or gene section code PIV P protein. The invention also provides separated polynucleotide for coding the virus genome or antigenome, a method of preparing the virus through expressing polynucleotide, and PIV immunogenic compositions including plenty immunity.

Description

[0001] The application date is June 15, 2000, the international application number PCT / US00 / 17066 entered the Chinese national phase on January 9, 2002, the application number is 00810120.5, and the invention name is "attenuated human-bovine chimeric parainfluenza Divisional application for virus (PIV) vaccine". [0002] Cross-references to related applications [0003] This application claims priority to US Provisional Patent Application 60 / 143,134, filed July 9,1999 by Bailly et al. Background of the invention [0004] Human parainfluenza virus type 3 (HPIV3) is a common cause of severe lower respiratory tract infections in young children and children under 1 year of age. It is second only to respiratory syncytial virus (RSV) in causing hospital admissions for viral lower respiratory disease in children in this age group (Collins et al., B.N. Fields Virology, p1205-1243,3 rd ed., vol.1., edited by Knipe et al., Lippincott-Raven Publishers, Philadelphia, 1996; Crowe et al...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N7/00C12N15/45C12N15/63A61K39/155A61P37/00C12N15/09A61K9/12A61K39/145A61P31/16C07K14/115C12R1/93
CPCC07K2319/00A61K2039/5256C12N2760/18622C07K14/005A61P31/16A61P37/00C12N15/11
Inventor 亚历山大·C·施密特马里奥·H·斯基亚道普洛斯彼得·L·柯林斯布赖恩·R·墨菲简·E·贝利安娜·P·德宾
Owner UNITED STATES OF AMERICA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com